Trulieve Cannabis 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 medical revenue was $230 million, up 4% year over year and sequentially from medical-only revenue in prior periods, and exceeded guidance.
- Gross profit was $148 million, or a 64% margin, up from $139 million in Q3 last year and $140 million in Q2 this year; gross margin improved by 1% year over year and sequentially.
- Adjusted EBITDA was $89 million, representing a 39% margin, and net income was $1 million; excluding nonrecurring items, net income would have been $18 million, or 9 cents per share.
- Operating cash flow was $74 million, capital expenditures were $29 million, and free cash flow totaled $45 million; quarter-end cash was $327 million and debt was $289 million.
- Retail revenue grew 2% sequentially, with traffic up 3% and units sold up 2%; Georgia and Pennsylvania contributed to growth.
- Trulieve had 208 dispensaries and 3.5 million square feet of production capacity, and sold over 10 million branded product units in its medical dispensaries during the quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and welcome to the Trulieve Cannabis Corporation Third Quarter 2026 Financial Results Conference Call. My name is Chuck, and I will be your conference operator today. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host for today's call, Ms. Christine Hersey, Chief Corporate Affairs and Strategy Officer for Trulieve. Please go ahead. Thank you.
Good morning, and thank you for joining us. During today's call, Kim Rivers, Chief Executive Officer, and Jan Reese, Chief Financial Officer, will deliver prepared remarks on the financial performance and outlook for Trulieve. Following the prepared remarks, we will open the call to questions. This morning, we reported third quarter 2026 results. A copy of our earnings press release and PowerPoint presentation may be found on the Investor Relations section of our website, www.trulieve.com. An archived version of today's conference call will be available on our website later today.
As a reminder, statements made during this call that are not historical fact constitute forward-looking statements, and these statements are subject to risks, uncertainties, and other factors that could cause our actual results to differ materially from our historical results or from our forecast, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report on Form 10-K, as well as our periodic quarterly filings. Although the company may voluntarily do so from time to time, it undertakes no commitment to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. During the call, management will also discuss certain financial measures that are not calculated in accordance with the U.S. Generally Accepted Accounting Principles, or GAAP.
We generally refer to these as non-GAAP financial measures. These measures should not be considered in isolation or as a substitute for Trulieve's financial results prepared in accordance with GAAP. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is available in our earnings press release that is an exhibit to our current report on Form 8-K that we furnished to the SEC today and can be found in the Investor Relations section of our website. Lastly, at times during our prepared remarks or responses to your questions, we may offer metrics to provide greater insight into the dynamics of our business or our financial results. Please be advised that we may or may not continue to provide these additional details in the future. I'll now turn the call over to our CEO, Kim Rivers.
Thank you, Christine. Good morning, everyone, and thank you for joining us today. We are thrilled to report third quarter results that exceeded guidance with higher revenue, margins, and cash generation. Third quarter results represent medical-only markets and our first full quarter listed on the New York Stock Exchange. This is an incredibly exciting time for our company. For anyone new to Trulieve, we are the largest U.S. medical cannabis operator with 208 dispensaries and 3.5 million square feet of production capacity. We are in the early stages of an accelerated growth period fueled by organic market development, acquisition opportunities, regulatory catalysts, and continued adoption of cannabis. Before we discuss our quarterly results, I would like to share some perspective on rescheduling and how Trulieve is positioned. The Trump administration made history by completing the first major cannabis policy reform in over 50 years.
Last December, President Trump issued an executive order opening the door for medical cannabis research and supporting rescheduling of state-licensed medical marijuana to Schedule III. Following the executive order in April, Attorney General Todd Blanche took two major actions. First, he issued a final order to reschedule state-licensed medical marijuana to Schedule III, and second, he restarted the rulemaking process to reschedule marijuana more broadly to Schedule III. The first action, rescheduling of state-licensed medical marijuana, triggered three major positive developments for Trulieve. One, registration with the DEA. Two, removal of the 280E punitive tax burden. And three, uplisting to the NYSE. I will touch briefly on each area. First, Trulieve registered all of its medical-only marijuana dispensaries and production facilities with the DEA, complying with the final order. Since then, the DEA has completed inspections and began issuing final registrations at all of our medical dispensaries and production sites.
With DEA registration and state licensure, Trulieve is a federally legal Schedule III operator. This is an important differentiator for us as it opens the door for new strategic partnerships and service providers. Second, concurrent with rescheduling of state-licensed medical marijuana, the Treasury Department issued a press release confirming that punitive 280E tax does not apply to state-licensed medical operators under Schedule III. From this year forward, we are taxed the same as any U.S. corporation. This parity is important because it improves profitability and cash flow while acknowledging the medical status of our business. Third, state-licensed medical marijuana rescheduling enabled Trulieve to list on the NYSE. As the largest U.S. medical operator, Trulieve was uniquely positioned to segregate its business into two parts, separating the non-medical mixed-use market from our medical-only business. Trulieve listed its medical-only Schedule III business on the NYSE in June.
Since uplisting, we have realized higher daily trading volume, reduced swap exposure, expanded access to institutional investors, and inclusion in several indices, such as the S&P Total Market Index and the Morningstar Total Stock Market Index. We expect Trulieve will be added to additional indices in the coming year. Altogether, Trulieve has realized meaningful benefits from rescheduling of state-licensed medical marijuana. Turning now to our third quarter results. As a reminder, results include markets serving only medical patients. During the third quarter, the team outperformed in multiple ways, delivering impressive execution in our core markets while rapidly expanding in Georgia and preparing to build out vertical operations in Texas. Third quarter revenue of $230 million grew 4% year-over-year and sequentially compared to medical-only revenue in prior periods. Medical revenue exceeded guidance and outperformed typical seasonal trends.
Compared to medical-only results last year, third quarter gross margin of 64% improved 1%, reflecting operational efficiencies, low production costs, and our disciplined approach to promotional activity. Adjusted EBITDA of $89 million, or 39% margin, was driven by expense control in our core business. During the quarter, we generated $74 million in operating cash flow, which contributed to our quarter-end cash balance of $327 million. Subsequent to quarter end, we fully repaid a $65 million mortgage secured by our cultivation campus in Jefferson County, Florida. The reduction in debt lowers annual interest expense, improving profitability and cash flow. Retail revenue grew 2% sequentially due to growth in Georgia and Pennsylvania. Traffic increased 3%, partially offset by a slight sequential decline in average basket size. Units sold were up 2%. In Georgia, traffic and units increased sevenfold with market expansion and new product types, including concentrates, flower, and vapes.
In Pennsylvania, higher traffic and strength in the wholesale channel contributed to revenue growth. Results in Florida were consistent with typical seasonal trends. Trulieve sold 55% more flower per store than the state average across 170 stores, totaling 657,000 ounces. We sold 1.4 billion milligrams of oil, more than two times the next highest competitor. Across our branded retail platform, customer trends have been consistent throughout the year, with some mid-tier customers leaning into value products, while the premium segment remains unchanged with a focus on exclusive top-shelf products. Our investment in Harvest performed well in the third quarter, with revenue growth and margin expansion compared to the second quarter, driven largely by growth in Ohio. As we approach year-end and the busy holiday season, our team is carrying the momentum forward. At the start of the year, we identified four strategic initiatives to focus on.
One, expanding access to cannabis. Two, investing in growth initiatives. Three, elevating our branded product portfolio. And four, growing our loyal customer base. Year to date, we have made significant progress in all four areas. First, I'd like to discuss expanding access to cannabis, which is central to our mission here at Trulieve. 2026 has been a pivotal year with historical federal policy changes and expansion in state markets such as Georgia. Federal rescheduling of state-licensed medical marijuana removes barriers for research, reduces stigma for patients and physicians, and provides a level playing field for lawful operators, enabling additional investments in patient access. We remain optimistic that broader rescheduling will happen in the near term. We expect the Treasury Department will issue additional guidance on tax treatment, including potential retroactive relief, following completion of the rescheduling process. Following the midterm elections, cannabis reform remains a central theme across the country.
We look forward to continuing to work with Congress to advance cannabis policy into 2027. Alongside rescheduling, we remain supportive of additional reform, including updated FinCEN guidance and SAFE Banking. These measures reduce friction for operators, support credit card payments in dispensaries, and ease restrictions on banking and service providers. Our second strategic growth priority is investing in growth initiatives, which includes both organic and acquisition opportunities. We believe Georgia and Texas present meaningful organic growth opportunities for Trulieve. In Georgia, following changes to the state medical marijuana program and federal rescheduling for state-licensed operators, we are pursuing two pathways for growth. The first is expansion of our licensed medical dispensary network. Today, we own and operate seven dispensaries that serve qualified patients with our branded products. Yesterday, we received approval to open our eighth and ninth dispensaries, which we anticipate will open in the coming months.
The state program is designed to provide expanded access as the patient count grows. With 80% patient growth since the start of the year, the patient count recently surpassed 60,000. We can request an additional location for every 10,000 patients that enroll. We plan to apply for our 10th dispensary this month once the patient count reaches 65,000 patients. The second growth area is wholesale distribution of branded products to independent pharmacies. In Georgia, independent pharmacies can register with the state and the DEA to dispense approved medical marijuana products to registered patients. Today, we are shipping to almost 20 pharmacies. While development of this channel remains ongoing, early progress is encouraging. Over 30 more pharmacies are ready to commence sales of Trulieve products pending licensure, and over 125 independent pharmacies previously expressed interest.
Our team is meeting with pharmacy owners across Georgia to discuss medical cannabis and share information on how to apply for state and DEA licenses. In support of growth in Georgia, we have been increasing production capacity since last spring. Our Georgia operations are fully vertically integrated, where we produce all of the cannabis products that we sell in our dispensaries. As I mentioned, third quarter units sold increased by seven times the amount sold in the second quarter. Newly launched in-house brands Modern Flower and Roll One accounted for 70% of our branded units sold in Georgia. Our team has done a fantastic job managing through the period of rapid growth. Today, we have adequate supply to service our current business, and we are adding capacity in stages into 2027 to meet growing demand in all channels.
While the Georgia market is rapidly expanding now, we believe Texas represents the largest medical cannabis opportunity in the U.S. Last December, Trulieve was awarded a conditional license. We are working through the process to convert the conditional award to a final license. We expect the next steps include completion of financial review and site inspections. Our initial production capacity is ready for inspection, and we have a robust retail pipeline of stores covering all regions. Pending final licensure, our team is ready to quickly ramp to serve Texas patients. New patients can enroll in the program through convenient telehealth consultations. Easy program entry, greater price variety, and increased awareness all support rapid program growth. We plan to replicate the success we've had in other markets like Florida and Georgia by scaling modularly as the patient count increases over time.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
